Primary Myelofibrosis - Pipeline Insight, 2026

DelveInsight's, "Primary Myelofibrosis - Pipeline Insight, 2026" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Primary Myelofibrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Primary Myelofibrosis: Understanding

Primary Myelofibrosis: Overview

Primary myelofibrosis (PMF) is a rare, chronic myeloproliferative neoplasm (MPN) characterized by abnormal blood-cell production and progressive fibrosis, or scarring, of the bone marrow. The accumulation of fibrous tissue disrupts normal hematopoiesis, reducing the bone marrow's ability to produce healthy blood cells. As the disease progresses, blood-cell production may shift to organs such as the spleen and liver, causing enlargement of these organs. PMF has a variable clinical course, ranging from an asymptomatic condition detected incidentally to progressive disease associated with significant complications and transformation to acute myeloid leukemia.

Many patients are asymptomatic during the early stages, with abnormalities detected during routine blood testing. Common manifestations include fatigue, weakness, shortness of breath due to anemia, and pain or fullness beneath the left ribs because of an enlarged spleen. Patients may also experience early satiety, bone pain, fever, night sweats, unexplained weight loss and reduced appetite. As the disease advances, low blood-cell counts can contribute to recurrent infections, easy bruising and bleeding, while severe splenomegaly may cause abdominal discomfort and impaired quality of life.

PMF develops when acquired genetic changes arise in hematopoietic stem cells, leading to abnormal cell proliferation and the release of signaling molecules that stimulate bone marrow fibrosis. Frequently identified driver mutations affect JAK2, CALR or MPL, which activate pathways involved in blood-cell growth and survival. These mutations are generally acquired rather than inherited, although familial susceptibility can occur in some cases. Abnormal megakaryocytes and inflammatory signaling contribute to collagen deposition in the marrow, impaired blood-cell formation and extramedullary hematopoiesis. The precise initiating cause remains unclear, and disease progression varies according to molecular, cytogenetic and clinical risk factors.

Diagnosis involves a complete blood count, peripheral blood smear, bone marrow biopsy and molecular testing for driver mutations. Typical findings may include anemia, abnormal white-cell or platelet counts, tear-shaped red blood cells and bone marrow fibrosis; testing also helps exclude other myeloid neoplasms.

Treatment depends on symptoms, disease risk and individual clinical characteristics, with observation appropriate for some asymptomatic, lower-risk patients. JAK inhibitors, including ruxolitinib, fedratinib, pacritinib and momelotinib, may help control splenomegaly and constitutional symptoms, while anemia may require transfusions or targeted supportive treatments. Allogeneic hematopoietic stem-cell transplantation remains the only established potentially curative treatment, but it is suitable only for selected patients.

"Primary Myelofibrosis - Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Primary Myelofibrosis pipeline landscape is provided which includes the disease overview and Primary Myelofibrosis treatment guidelines. The assessment part of the report embraces, in depth Primary Myelofibrosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Primary Myelofibrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• The companies and academics are working to assess challenges and seek opportunities that could influence Primary Myelofibrosis R&D. The therapies under development are focused on novel approaches to treat/improve Primary Myelofibrosis.

Primary Myelofibrosis Emerging Drugs Chapters

This segment of the Primary Myelofibrosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Primary Myelofibrosis Emerging Drugs

Pelabresib: Novartis

Pelabresib is an investigational oral bromodomain and extraterminal domain (BET) inhibitor being developed by Novartis for primary myelofibrosis and other forms of myelofibrosis. It targets BET proteins, particularly BRD4, to modulate the expression of genes involved in inflammation, fibrosis and abnormal blood-cell proliferation. Pelabresib is being evaluated in combination with ruxolitinib, a JAK1/JAK2 inhibitor, to improve spleen volume reduction and disease-related symptoms. The Phase III MANIFEST-3 study is comparing pelabresib plus ruxolitinib against ruxolitinib alone in JAK-inhibitor-naive patients with myelofibrosis.

Nuvisertib: Sumitomo Pharma

Nuvisertib (TP-3654) is an investigational, oral selective PIM1 kinase inhibitor developed by Sumitomo Pharma for primary and secondary myelofibrosis. It targets PIM1, a signaling kinase involved in abnormal blood-cell proliferation, cell survival and disease progression, with the aim of reducing myelofibrosis-associated symptoms and splenomegaly. Nuvisertib is also being investigated in combination with ruxolitinib or momelotinib to improve treatment responses in patients with suboptimal responses to, or resistance to, prior JAK inhibitor therapy. It is being evaluated in an ongoing Phase I/II clinical trial assessing safety, tolerability, pharmacokinetics and preliminary efficacy.

LY5830966: Eli Lilly and Company

LY5830966 (AJ1-11095) is an investigational, oral, first-in-class type II Janus kinase 2 (JAK2) inhibitor being developed by Ajax Therapeutics, a subsidiary of Eli Lilly, for primary and secondary myelofibrosis. It selectively binds JAK2 in its inactive conformation, aiming to suppress aberrant JAK2 signaling that drives abnormal blood-cell production and bone marrow fibrosis. The approach is designed to offer a treatment option for patients who have failed or relapsed after treatment with existing type I JAK2 inhibitors. LY5830966 is being evaluated in a Phase I clinical trial assessing safety, tolerability, pharmacokinetics and preliminary clinical activity.

Primary Myelofibrosis: Therapeutic Assessment

This segment of the report provides insights about the different Primary Myelofibrosis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Primary Myelofibrosis

There are approx. 25+ key companies which are developing the therapies for Primary Myelofibrosis. The companies which have their Primary Myelofibrosis drug candidates in the most advanced stage, i.e. Phase III include Novartis.

Phases

DelveInsight's report covers around 30+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Primary Myelofibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Primary Myelofibrosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Primary Myelofibrosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Primary Myelofibrosis drugs.

Primary Myelofibrosis Report Insights

• Primary Myelofibrosis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Primary Myelofibrosis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Primary Myelofibrosis drugs?
• How many Primary Myelofibrosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Primary Myelofibrosis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Primary Myelofibrosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Primary Myelofibrosis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Novartis
• Eli Lilly and Company
• Sumitomo Pharma
• Disc Medicine, Inc
• Prelude Therapeutics
• Merck Sharp & Dohme LLC
• Hangzhou GluBio Pharmaceutical Co., Ltd.
• PharmaEssentia Corporation
• Chengdu Zenitar Biomedical Technology
• Takeda
• Keros Therapeutics
• Phoenix Molecular Designs
• Cellenkos

Key Products

• Pelabresib
• LY5830966
• Nuvisertib
• DISC-0974
• PRT12396
• Bomedemstat
• GLB-001
• Ropeginterferon alfa-2b
• Flonoltinib Maleate
• Elritercept
• PMD-026
• CK0804